Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?

ABSTRACT:

Purpose

To investigate whether the relation between estrogen-progestagen menopausal hormone therapy (EP-MHT) and breast cancer risk varies according to the delay between menopause onset and treatment initiation.

Participants and methods

Between 1992 and 2005, 1,726 invasive breast cancers were identified among 53,310 postmenopausal women from the French E3N cohort (mean duration of follow-up, 8.1 years). Hazard ratios (HRs) and CIs were estimated using Cox models, with MHT never users as the reference.

Results

Among recent users of EP-MHT, the risk of breast cancer varied according to the timing of treatment initiation. This variation was confined to short durations of use (< or = 2 years): the HR was 1.54 (95% CI, 1.28 to 1.86) for short treatments initiated in the 3

SUBMITTER: Fournier A 

PROVIDER: S-EPMC6413836 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature